Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 21, 2014Journal of Neurology Neurosurgery & PsychiatryOpen Access

Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy

View Full Paper
Ask AI
Bookmark
Share

Authors

OTOrla TuohyUniversity Hospital WaterfordLCLisa CostelloeBeaumont HospitalGHGrant Hill-CawthorneThe University of Sydney

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Tuohy et al. (2014) studied this question.

synapsesocial.com/papers/6a6f80ef660549caf2c40b96https://doi.org/10.1136/jnnp-2014-307721
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial2012 · 268 citations
  2. 2The Measurement of Observer Agreement for Categorical Data1977 · 81,660 citations
  3. 3Rating neurologic impairment in multiple sclerosis1983 · 15,120 citations
  4. 4Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation2013 · 204 citations
  5. 5Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis2011 · 196 citations